Symeres has welcomed Jurgen Berendsen back to the company as Chief Financial Officer (CFO), following his earlier role as Senior Group Controller.
Jurgen brings more than 15 years of financial leadership experience across both professional services and international trade sectors, including roles at KPMG, Hoogwegt International, and most recently Royal Reesink, where he served as Vice President of Finance and Control. He returns to Symeres at a pivotal time, driven by a strong belief in our mission and potential. He brings not only deep institutional knowledge, but also valuable external perspective gained from leading finance functions in other complex organizations.
“Returning to Symeres as CFO is an extremely exciting opportunity,” said Jurgen Berendsen. “Symeres has all the ingredients for long-term growth and success. I am proud to join a strong and dedicated leadership team who is unwaveringly committed to delivering optimal outcomes for customers, employees, and shareholders alike.”
Jurgen previously joined Symeres in 2022 to take on the newly created role of Group Financial Controller. During his time at the company, he played a key role in the implementation of major transformation programs, including finance systems (ERP) upgrades, compliance initiatives, and business continuity planning. His close collaboration with the board and hands-on approach during the company’s restructuring phase earned him wide respect across the organization.
“Jurgen’s appointment comes at a critical moment for Symeres as we strengthen our operational and financial foundations to scale more effectively,” said Guillaume Jetten, CEO of Symeres. “He combines strategic vision with a deep understanding of our business and culture. His return brings continuity and a partner mindset that will benefit the whole organization.”
In his new role, Jurgen will oversee financial operations across our global footprint, working closely with the executive team to support sustainable growth. His focus will be on building financial resilience, driving operational integration across sites in the Netherlands, Finland, and the U.S., and championing transparency and trust, both internally and with clients.
Reflecting on his decision to return, Jurgen cited a belief in the mission and a shared vision for how Symeres can adapt to market challenges and emerge stronger. “The tone at the top is vital, but equally important is how we translate that transparency and accountability across every customer interaction,” he said.
With an ambition to drive long-term customer partnerships and innovate, such as AI and integrated delivery models, Jurgen’s financial stewardship is expected to be instrumental in Symeres’ evolution as a best-in-class partner for biopharma organizations worldwide.
Latest news
What are the top drug development trends for 2026? Exemplify CSO Paul O’Shea discusses what to watch
Symeres earns first SBTi approval as part of long-term sustainability journey
Symeres appoints Gabriella Gentile as Chief Operating Officer to drive transatlantic growth
Symeres announces acquisition of DGr Pharma
Symeres and Yoneda Labs use AI to optimize cross-coupling reactions
New production lines D1 and D2 at our Prague site
New NMR technology – meet “Maggie”
Symeres announces leadership evolution
Official opening of new Oncolines home, the Marie Curie Building at the Pivot Park in Oss, the Netherlands
New equipment at Exemplify
New 100 L vessels in Groningen
Organix: New facility
Innovative macrocycles as powerful Mcl-1 inhibitors
Oncolines unveils new state-of-the-art laboratories
Peter Molenveld assumes role as secretary of KNCV (Royal Netherlands Chemical Society)
Chiral chemistry: in the DNA of Symeres
π-facial selectivity in the Diels–Alder reaction of glucosamine-based chiral furans and maleimides
Symeres acquires Oncolines, further strengthening its drug discovery and biology capabilities
Symeres acquires Exemplify BioPharma, further strengthening its strategic foothold in the US
Expansion of solid-state center of excellence
Symeres acquires Massachusetts-based Organix Inc., adding lipids expertise and creating a strategic foothold in the US market
Expanding the toolbox: Resolving racemates
Symeres joins forces with Keensight Capital
Speak with our experts
Let’s discuss how Symeres can support the discovery and development of your next breakthrough